Navigation Links
Cleveland Clinic Selects Laparoendoscopic Single-Site Surgery (LESS) as One of the Top Ten Innovations of 2009

Founder of Leader In LESS Instrumentation Is Selected for Industry Leader LESS Panel at Cleveland Clinic Medical Innovation Summit

FRAMINGHAM, Mass., Jan. 29 /PRNewswire/ -- Cambridge Endo, a pioneer in the rapidly emerging LESS (also called Single Port Access Laparoscopic Surgery or SPA) market, is pleased to announce that its president and founder, Woojin Lee, was among the industry leaders selected to be on a LESS panel at the Cleveland Clinic Medical Innovation Summit. Cambridge Endo developed, manufactures and markets the innovative Autonomy(TM) Laparo-Angle(TM) articulating instruments which, it believes, is the enabling technology that will drive the rapid uptake of this major advance in laparoscopic surgery.

In traditional laparoscopic surgery, the surgeon makes three to six "keyhole" incisions in multiple sites, inserts instrumentation into each "keyhole" and performs the surgery. In LESS/SPA, only one incision is made through the umbilicus (navel). All of the instruments go through this single "keyhole." Said Lee, "LESS/SPA has been called 'scarless' surgery."

According to the Cleveland Clinic, the key criteria used in selecting LESS/SPA as one of the top 10, "game changing" innovations of 2009 were:

  • "Have significant potential for short-term clinical impact (either a major improvement in patient benefit or an improved function that enhances healthcare delivery)
  • Have a high probability of success
  • Be on the market or close to being introduced
  • Have sufficient data available to support its nomination."

Inderbir S. Gill, M.D., Chairman of Urology at the Cleveland Clinic commented, "[we] performed LESS live-donor nephrectomies in nine consecutive kidney donors for kidney transplantation. All aspects of kidney harvesting were completed though the navel. Instead of a visible six-inch scar and a six-week recovery period, patients recovered within two weeks and had a tiny scar hidden by their belly button. Because it only uses one port with multiple channels for the surgeon to simultaneously pass various surgical instruments, LESS may also reduce complications that might occur after traditional open and even laparoscopic abdominal surgery. My patients report less discomfort and have faster recoveries compared to those undergoing traditional laparoscopy." According to the clinic, the return to work time for single port surgery donors is about 17 days vs. 51 for traditional multi-incision laparoscopic procedures.

Commented Lee, "Donor nephrectomy is but one of the many laparoscopic surgical procedures that, we believe, will be converting to LESS/SPA in the coming years. Already, LESS/SPA procedures have been performed with Autonomy articulating instruments in many general, urologic, and gynecologic surgical procedures. Together, over two million of these procedures are currently performed laparoscopically in the U.S. each year. This is a very large addressable market."

About Cambridge Endo

Cambridge Endo is a privately held medical device company that designs, develops and manufactures innovative articulating laparoscopic instruments. The Autonomy(TM) Lapro-Angle(TM) product line is designed to be an enabling technology for LESS/SPA. Autonomy articulating instruments are also used in many traditional laparoscopic procedures by general, bariatric, urologic, and gynecologic surgeons.

Cambridge Endo is headquartered in Framingham, MA. For more information about Cambridge, please visit

    Woojin Lee, Ph.D.
    508-405-0790 ext. 104

SOURCE Cambridge Endo
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
2. Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009
3. Cleveland Clinic Recognizes Circulating Tumor Cell Technology as Top Medical Innovation for 2009
4. NanoMedicine Summit Returns to Cleveland, September 25-26
5. University Hospitals Case Medical Center, Cleveland, USA and Cardialysis BV, Rotterdam, the Netherlands Enter Strategic Alliance to Found Cardialysis Cleveland
6. Cleveland Clinic and Rutgers to Lead Newly Formed Institute for War Wounded
7. Siemens Signs Multi-Year Agreement With Cleveland Clinic to Deploy Enterprise-Wide Cardiology PACS
8. Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007
9. Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease
10. Perceptive Informatics Reaches Key Milestone Marking 10 Million IVRS Interactions In Support of Clinical Trials
11. ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
(Date:3/22/2016)... PROVO and SANDY, ... Screening Ontario (NSO), which operates the highest sample volume ... testing, and Tute Genomics and UNIConnect, leaders in clinical ... today announced the launch of a project to establish ... testing panel. NSO has been contracted ...
Breaking Biology News(10 mins):